Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
높은 배당금
회사는 높은 배당금을 지급하는 회사로, 최신 배당금 지급 비율은 34.38%입니다.
과대 평가된
회사의 최신 PE은 14.25로, 최근 3년 기준 높은 백분위 범위에 속합니다.
기관 매도
최신 기관 보유 주식 수는 239.27M주이며, 전 분기 대비 1.64% 감소했습니다.
어빙 칸가 보유
스타 투자자 어빙 칸이(가) 이 주식 2.48M주를 보유하고 있습니다.
시장 활동 감소
회사는 투자자들의 관심이 줄어들어, 최근 20일간 회전율이 -0.41입니다.